Labor, Human, and Civil Rights Trade Policy Act

-Ongoing implementation of payment and regulatory issues for the Medicare Advantage program. CMS-4182-P/CMS-4182-CN: Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2019. Medical utilization management and Medicare Advantage program policy and operations. -Issues related to the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. -Proposals that impact Medicare Part D such as formulary requirements, pharmacy benefit manager (PBM) disclosure provisions, closing the Part D coverage gap and direct negotiation of prescription drug prices. -Policy and technical changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2020 (CMS-4185-P). -Pharmacy Direct and Indirect Remuneration (DIR) H.R. 1034, the Phair Pricing Act of 2019; S.640, the Phair Pricing Act of 2019; H.R. 803, the Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 1035, the Improving Transparency and Accuracy in Medicare Part D Spending Act. -Medicare Part B reforms. S 476, the Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; S.657, the Drug Price Transparency Act. Issues related to H.R. 2115, Public Disclosure of Drug Discounts Act. -Issues related to H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability And Reporting (STAR) Act. -The Prescription Drug Pricing Reduction Act of 2019 (Chairman's Mark). -H.R. 2996, the More Efficient Tools to Realize Information For Consumers (METRIC) Act.

Client expense: $2,300,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)

H.R.2996, More Efficient Tools to Realize Information for Consumers (METRIC) Act, Prescription Drug Monitor the following: Pandemic and All-Hazards Preparedness Reauthorization, Medical Countermeasures Prescription drug reform related issues S.1895, Lower Health Care Costs Act, generally Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First, June 24, 2019

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the implementation of the drug pricing RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs; monitored issues related to the safe harbor protection. H.R. 2996, The METRIC Act.

Client expense: Not reported · Firm income: $60,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE